Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic
kinase activity that transduces important growth factor signaling from the extracellular milieu …

The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …

Purpose: Epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer
(NSCLC) might be predictive for clinical response to EGFR inhibitor treatment. However …

Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …

Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …

Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …

Despite tremendous progress in the last decade, lung adenocarcinoma still represents a
tumor with unfavorable prognosis when detected at advanced clinical stage. High-stage …

In 2004 remarkable clinical responses in non-small-cell lung cancer (NSCLC) patients
treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib …

Context.—Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are molecular-
targeted drugs that are innovatively effective for non–small cell lung carcinomas with EGFR …

Somatic mutations in the epidermal growth factor receptor (EGFR) have been identified in
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …